Notwithstanding, it is usually found that Rev augments anti-tumor immune activity, as reported by Chung et al., who showed that, at least for post ASCT lenalidomide maintenance therapy, Tregs declined as CD8+ T cells expanded during early lymphocyte recovery [30]. This evidence concerns the gene CD8A and neoplasm.